BCR-ABL1 Screening dPCR OncoKit

Detection and quantification of BCR-ABL1 rearrangements and ABL1 messenger RNA (mRNA) transcripts from peripheral blood complementary DNA (cDNA) samples in patients diagnosed or suspected of chronic myeloid leukemia (CML) positive for t(9;22)

24 rxn (dehydrated/freeze-dried)

PCR digital (dPCR)

IMG-424

QuantStudioTM Absolute Q Digital PCR System (ThermoFisher Scientific)

  • Quantitative multiplex assay: detection and quantification of BCR-ABL1 rearrangements and ABL1 mRNA transcripts from complementary DNA (cDNA) samples extracted from peripheral blood by dPCR.
  • BCR-ABL1 Screening dPCR OncoKit is intended for use in research and is aimed exclusively at healthcare workers and professionals working in molecular biology.

BCR-ABL1 Screening dPCR OncoKit is designed to detect and quantify BCR-ABL1 and ABL1 messenger RNA (mRNA) transcripts. The kit utilizes digital PCR (dPCR), a highly sensitive, precise, and accurate end-point PCR method that allows absolute quantification of a sample subdivided into 20,000 partitions.

The kit employs a combination of oligonucleotides and fluorescent hydrolysis probes in a multiplex assay for relative quantification of the mutated allele against the wild-type allele.

  • Sample type: cDNA from peripheral blood.
  • Positive control: Synthetic Synthetic DNA with the 3 rearrangements, M-BCR, m-BCR and µ-BCR, and a ABL1 region as the endogenous control
  • Limit of detection: 0,1%
  • Number of reactions per sample: 1
  • Number of targets: 3 (fusiones M-BCR, m-BCR y µ-BCR y región de ABL1 como endógeno)
  • Duration of the dPCR program: 1 h 45 min.

BCR-ABL1 Screening dPCR OncoKit

Fill in the form to request this kit.

Call us at +34 963 212 340

Or write to us at info@healthincode.com

"*" indicates required fields

This field is for validation purposes and should be left unchanged.